Sandoz Launches Generic Version Of Toprol XL(R) 50 Mg ER Tablet

Aug 02, 2007, 01:00 ET from Sandoz

    PRINCETON, N.J., Aug. 2 /PRNewswire/ -- Sandoz introduced metoprolol
 succinate 50 mg extended release tablets, a generic equivalent of Toprol
 XL(R), in the U.S. today. Metoprolol succinate 50 mg ER is a beta-blocker
 used to treat angina, heart failure, and high blood pressure.
     "We are pleased to be first to the market with a 50 milligram extended
 release generic version of this drug," said Bernhard Hampl, chief executive
 officer of Sandoz Inc. "It is a strong complement to our existing product
 line, which includes metoprolol succinate 25 milligram ER tablets."
     According to IMS Health data, the 50 mg tablet of Toprol XL, with sales
 of $643 million in the U.S. for the 12 months ending April 2007, is the
 most widely dispensed strength of the drug.
     About Sandoz
     Sandoz, a division of the Novartis group, is a global leader in the
 field of generic pharmaceuticals, offering a wide array of high-quality,
 affordable products that are no longer protected by patents. Sandoz has a
 portfolio of more than 840 compounds in over 5,000 forms worldwide and
 sells its products in more than 110 countries. Key product groups include
 antibiotics, treatments for central nervous system disorders,
 gastrointestinal medicines, cardiovascular treatments and hormone
 therapies. Sandoz develops, produces and markets these drugs along with
 pharmaceutical and biotechnological active substances and anti-infectives.
 In addition to the strong organic growth in recent years, Sandoz has made a
 series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal
 (Germany) and Eon Labs (U.S.). In 2006, Sandoz employed approximately
 21,000 people worldwide and posted sales of USD 6 billion.
     The foregoing release may contain forward-looking statements regarding
 potential additional marketing approvals or future sales of metoprolol
 succinate. Any such forward looking statements involve known and unknown
 risks, uncertainties and other factors that may cause actual results with
 metoprolol succinate to be materially different from any future results,
 performance or achievements expressed or implied by such statements. There
 can be no guarantee that metoprolol succinate will receive any additional
 marketing approvals in any other countries, or that it will reach any
 particular sales levels. Management's expectations regarding metoprolol
 succinate could be affected by various risks and factors referred to in the
 company's current Form 20-F on file with the US Securities and Exchange
 Commission. Should one or more of these risks or uncertainties materialize,
 or should underlying assumptions prove incorrect, actual results may vary
 materially from those anticipated, believed, estimated or expected. Sandoz
 is providing this information as of this date and does not undertake any
 obligation to update any forward-looking statements contained in this
 document as a result of new information, future events or otherwise.
     Toprol XL(R) is a registered trademark of AstraZeneca PLC.